BACKGROUND: The level of minimal residual disease (MRD) prior to allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an independent prognostic factor for outcome of pediatric patients with high-risk acute lymphoblastic leukemia (ALL). Retrospective studies which used (semi-) quantitation of clone-specific immunoglobulin/T-cell receptor (Ig/TCR) rearrangements have documented the feasibility and practicality of this technique. This approach has also been disputed due to the occurrence of clonal evolution and generally high MRD levels prior to HSCT. PROCEDURE: In our prospective study, MRD before and after HSCT was monitored using quantitative real-time PCR in a cohort of 36 children with ALL consecutively transplanted in our center between VIII/2000 and VII/2004. RESULTS: In 25 of 36 patients, MRD level prior HSCT was assessed. Seventeen patients were classified as MRD-negative and eight were MRD-positive up to 9 x 10(-2). In MRD-positive subgroup, seven events (six relapses) occurred post-transplant in striking contrast to only one relapse in MRD-negative subgroup (event-free survival (EFS) log-rank P < 0.0001). MRD proved to be the only significant prognostic factor in a multivariate analysis (P < 0.0001). Adoptive immunotherapy including donor lymphocyte infusions in patients with adverse dynamics of MRD after HSCT had only limited and/or temporary effect. Clonal evolution did not present a problem precluding MRD monitoring in any of patients suffering a post-transplant relapse. CONCLUSIONS: We show that MRD quantitation using clonal Ig/TCR rearrangements successfully assesses the risk in pediatric ALL patients undergoing allogeneic HSCT. As our ability to treat detectable MRD levels after HSCT is very limited, alternative strategies for MRD-positive patients prior HSCT are necessary. (c) 2006 Wiley-Liss, Inc.
BACKGROUND: The level of minimal residual disease (MRD) prior to allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an independent prognostic factor for outcome of pediatric patients with high-risk acute lymphoblastic leukemia (ALL). Retrospective studies which used (semi-) quantitation of clone-specific immunoglobulin/T-cell receptor (Ig/TCR) rearrangements have documented the feasibility and practicality of this technique. This approach has also been disputed due to the occurrence of clonal evolution and generally high MRD levels prior to HSCT. PROCEDURE: In our prospective study, MRD before and after HSCT was monitored using quantitative real-time PCR in a cohort of 36 children with ALL consecutively transplanted in our center between VIII/2000 and VII/2004. RESULTS: In 25 of 36 patients, MRD level prior HSCT was assessed. Seventeen patients were classified as MRD-negative and eight were MRD-positive up to 9 x 10(-2). In MRD-positive subgroup, seven events (six relapses) occurred post-transplant in striking contrast to only one relapse in MRD-negative subgroup (event-free survival (EFS) log-rank P < 0.0001). MRD proved to be the only significant prognostic factor in a multivariate analysis (P < 0.0001). Adoptive immunotherapy including donor lymphocyte infusions in patients with adverse dynamics of MRD after HSCT had only limited and/or temporary effect. Clonal evolution did not present a problem precluding MRD monitoring in any of patients suffering a post-transplant relapse. CONCLUSIONS: We show that MRD quantitation using clonal Ig/TCR rearrangements successfully assesses the risk in pediatric ALL patients undergoing allogeneic HSCT. As our ability to treat detectable MRD levels after HSCT is very limited, alternative strategies for MRD-positive patients prior HSCT are necessary. (c) 2006 Wiley-Liss, Inc.
Authors: Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia Journal: Haematologica Date: 2010-02-23 Impact factor: 9.941
Authors: Veronika Bachanova; Michael J Burke; Sophia Yohe; Qing Cao; Karamjeet Sandhu; Timothy P Singleton; Claudio G Brunstein; John E Wagner; Michael R Verneris; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2012-03-16 Impact factor: 5.742
Authors: C Eckert; N Hagedorn; L Sramkova; G Mann; R Panzer-Grümayer; C Peters; J-P Bourquin; T Klingebiel; A Borkhardt; G Cario; J Alten; G Escherich; K Astrahantseff; K Seeger; G Henze; A von Stackelberg Journal: Leukemia Date: 2015-03-09 Impact factor: 11.528
Authors: M Kotrova; V H J van der Velden; J J M van Dongen; R Formankova; P Sedlacek; M Brüggemann; J Zuna; J Stary; J Trka; E Fronkova Journal: Bone Marrow Transplant Date: 2017-02-27 Impact factor: 5.483
Authors: Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne Journal: Biol Blood Marrow Transplant Date: 2010-06-14 Impact factor: 5.742